| scholarly article | Q13442814 |
| P50 | author | Yves Dauvilliers | Q30500684 |
| Chrisophe Hirtz | Q67221786 | ||
| Audrey GABELLE | Q67221789 | ||
| Jérôme Vialaret | Q88373339 | ||
| P2093 | author name string | Sylvain Lehmann | |
| Nora Nowak | |||
| P2860 | cites work | Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle | Q24644961 |
| Statistical methods for assessing agreement between two methods of clinical measurement | Q26778461 | ||
| Amyloid-β diurnal pattern: possible role of sleep in Alzheimer's disease pathogenesis | Q27026835 | ||
| Crystal structure of the human OX2 orexin receptor bound to the insomnia drug suvorexant | Q27696899 | ||
| A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains | Q28145391 | ||
| Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior | Q28266541 | ||
| Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation | Q29615680 | ||
| Neurons containing hypocretin (orexin) project to multiple neuronal systems | Q29619641 | ||
| Hypocretin and brain β-amyloid peptide interactions in cognitive disorders and narcolepsy. | Q33737141 | ||
| Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma | Q33794491 | ||
| The hypocretin/orexin ligand-receptor system: implications for sleep and sleep disorders. | Q33910875 | ||
| Reduced number of hypocretin neurons in human narcolepsy | Q33923479 | ||
| The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias | Q34153927 | ||
| Hypocretin (orexin) loss in Alzheimer's disease | Q34183012 | ||
| Selected reaction monitoring-based proteomics: workflows, potential, pitfalls and future directions | Q34279143 | ||
| Cerebrospinal fluid melanin-concentrating hormone (MCH) and hypocretin-1 (HCRT-1, orexin-A) in Alzheimer's disease | Q34344331 | ||
| Localized loss of hypocretin (orexin) cells in narcolepsy without cataplexy | Q34611455 | ||
| The role of hypocretins (orexins) in sleep regulation and narcolepsy. | Q34674865 | ||
| Potential role of orexin and sleep modulation in the pathogenesis of Alzheimer's disease | Q34708307 | ||
| CSF hypocretin-1 levels in narcolepsy, Kleine-Levin syndrome, and other hypersomnias and neurological conditions | Q35560285 | ||
| How amyloid, sleep and memory connect | Q36629693 | ||
| Narcolepsy with cataplexy | Q36733271 | ||
| Endogenous interference in immunoassays in clinical chemistry. A review | Q37996345 | ||
| Overview of orexin/hypocretin system | Q38027688 | ||
| Quantitative Clinical Chemistry Proteomics (qCCP) using mass spectrometry: general characteristics and application | Q38062812 | ||
| Interactions of the histamine and hypocretin systems in CNS disorders. | Q38534913 | ||
| Cataplexy--clinical aspects, pathophysiology and management strategy. | Q47867265 | ||
| Orexinergic system dysregulation, sleep impairment, and cognitive decline in Alzheimer disease. | Q48022782 | ||
| CSF beta-amyloid levels are altered in narcolepsy: a link with the inflammatory hypothesis? | Q48119299 | ||
| Relationship between CSF hypocretin levels and hypocretin neuronal loss | Q48602913 | ||
| Advances in multiplexed MRM-based protein biomarker quantitation toward clinical utility. | Q50873210 | ||
| CLSI EP17-A protocol: a useful tool for better understanding the low end performance of total prostate-specific antigen assays. | Q51050011 | ||
| Hypocretin (orexin) activation and synaptic innervation of the locus coeruleus noradrenergic system. | Q51435079 | ||
| Interference with clinical laboratory analyses | Q72792144 | ||
| False-positive immunoassay results: a multicenter survey of erroneous immunoassay results from assays of 74 analytes in 10 donors from 66 laboratories in seven countries | Q78448084 | ||
| The dynamic range problem in the analysis of the plasma proteome | Q84260348 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cerebrospinal fluid | Q54196 |
| P304 | page(s) | 25162 | |
| P577 | publication date | 2016-05-11 | |
| P1433 | published in | Scientific Reports | Q2261792 |
| P1476 | title | From radioimmunoassay to mass spectrometry: a new method to quantify orexin-A (hypocretin-1) in cerebrospinal fluid | |
| P478 | volume | 6 |
| Q61444179 | HPLC analysis of CSF hypocretin-1 in type 1 and 2 narcolepsy |
| Q47728004 | Hypocretin measurement: shelf age of radioimmunoassay kit, but not freezer time, influences assay variability |
| Q56627695 | Narcolepsy |
| Q92035817 | Narcolepsy - clinical spectrum, aetiopathophysiology, diagnosis and treatment |
| Q47780791 | Orexin and Alzheimer's Disease |
| Q47747609 | Temporal Changes in the Cerebrospinal Fluid Level of Hypocretin-1 and Histamine in Narcolepsy. |
Search more.